FDA gives emergency-use approval for Abbott's $5, 15-minute COVID-19 test, though not for home use
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
You are now subscribed
Your newsletter sign-up was successful
Abbott Laboratories said Wednesday that the Food and Drug Administration had granted it emergency-use authorization for its quick, inexpensive COVID-19 antigen test, and it plans to ship tens of millions of the tests in September. The test, called the BinaxNOW COVID-19 Ag Card, is about the size of a credit card, will cost $5 each, and returns results in about 15 minutes, Abbott says. It works kind of like a pregnancy test but still involves and nasal swab and needs to be administered by medical professionals, typically in a doctor's office or by a school nurse. It won't be sold directly to consumers for home use.
This isn't the first rapid COVID-19 test given a provisional green light by the FDA. Similar antigen tests are processed in boxlike machines and cost anywhere from $15 to $50, The Wall Street Journal reports. Abbott also makes a rapid-response molecular test used in the White House, though that was shown to be returning frequent false negatives. The newly approved antigen test has been shown to accurately detect positive cases about 97 percent of the time, Abbott said.
The test should help meet a growing demand for cheap, less-accurate COVID-19 tests that some public health officials argue the U.S. needs to return to school and work.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
